Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | CCR10 | P46092 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9059238 | 0.93 | F2 (0.43) | F2 | |
| SCHEMBL9056480 | 0.83 | F2 (0.42) | F2 | |
| SCHEMBL9056137 | 0.82 | F2 (0.40) | F2 | |
| SCHEMBL9054863 | 0.80 | F2 (0.40) | F2ITGB3ITGAVITGA2B | |
| SCHEMBL9058550 | 0.74 | F2 (0.75) | F2 | |
| SCHEMBL9055655 | 0.73 | F2 (0.39) | F2ITGB3ITGAVITGA2BCCR10 | |
| SCHEMBL9055067 | 0.72 | F2 (0.75) | F2 | |
| SCHEMBL9062258 | 0.72 | F2 (0.45) | F2ITGB3ITGAVITGA2B | |
| SCHEMBL9057780 | 0.71 | ITGB3 (0.39) | F2MMP1MMP2MMP3MMP8 | |
| SCHEMBL9055877 | 0.70 | F2 (0.47) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996002517-A1 | SUBSTITUTED ARYLSULFONAMIDES, THEIR PREPARATION AND USE AS THROMBIN-INHIBITING MEDICAMENTS | DR. KARL THOMAE GMBH (DE) | 1996-02-01 | — | — | WO | disclosed |